Severe insulin resistance syndromes
Angeliki M. Angelidi, … , Andreas Filippaios, Christos S. Mantzoros
Angeliki M. Angelidi, … , Andreas Filippaios, Christos S. Mantzoros
Published February 15, 2021
Citation Information: J Clin Invest. 2021;131(4):e142245. https://doi.org/10.1172/JCI142245.
View: Text | PDF
Review Series Article has an altmetric score of 36

Severe insulin resistance syndromes

Abstract

Severe insulin resistance syndromes are a heterogeneous group of rare disorders characterized by profound insulin resistance, substantial metabolic abnormalities, and a variety of clinical manifestations and complications. The etiology of these syndromes may be hereditary or acquired, due to defects in insulin potency and action, cellular responsiveness to insulin, and/or aberrations in adipose tissue function or development. Over the past decades, advances in medical technology, particularly in genomic technologies and genetic analyses, have provided insights into the underlying pathophysiological pathways and facilitated the more precise identification of several of these conditions. However, the exact cellular and molecular mechanisms of insulin resistance have not yet been fully elucidated for all syndromes. Moreover, in clinical practice, many of the syndromes are often misdiagnosed or underdiagnosed. The majority of these disorders associate with an increased risk of severe complications and mortality; thus, early identification and personalized clinical management are of the essence. This Review aims to categorize severe insulin resistance syndromes by disease process, including insulin receptor defects, signaling defects, and lipodystrophies. We also highlight several complex syndromes and emphasize the need to identify patients, investigate underlying disease mechanisms, and develop specific treatment regimens.

Authors

Angeliki M. Angelidi, Andreas Filippaios, Christos S. Mantzoros

×

Figure 2

Patients with congenital generalized, familial partial, and acquired lipodystrophies display selective and variable adipose tissue loss.

Options: View larger image (or click on image) Download as PowerPoint
Patients with congenital generalized, familial partial, and acquired lip...
(A) CGL1 and CGL2 may present with a generalized lack of fat, extreme muscularity, acanthosis nigricans in the groin, abdomen, or axillae, and acromegaloid features. (B) Familial partial lipodystrophy such as the Dunnigan variety may manifest as loss of fat from the trunk and upper and lower extremities and excess fat accumulation in the face and neck. (C) Other familial partial lipodystrophies are characterized by loss of fat from the face, neck, arms, and legs and excess fat accumulation in the trunk. (D) Similarly, acquired lipodystrophy associated with HIV infection may display as loss of fat from the face, arms, and legs; in certain cases, increased abdominal fat; and a “buffalo hump.” (E) Acquired partial lipodystrophy is characterized by loss of subcutaneous fat from the face, neck, arms, thorax, and abdomen and simultaneously excessive amounts of subcutaneous fat in the legs. (F) Acquired generalized lipodystrophy is characterized by loss of fat from large areas of the body, particularly the face, arms, and legs.